{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Risperidone&page=4", "query": { "intervention": "Oral Risperidone", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 74, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Risperidone&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Risperidone&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T22:19:51.192Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04512066", "title": "A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia, Schizoaffective Disorder" ], "interventions": [ { "name": "RO6889450", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 287, "start_date": "2020-09-08", "completion_date": "2022-06-21", "has_results": true, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-10-03T22:19:51.192Z", "location_count": 24, "location_summary": "Little Rock, Arkansas • Bellflower, California • Culver City, California + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04512066" }, { "nct_id": "NCT00330551", "title": "Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Oral Risperidone", "type": "DRUG" }, { "name": "Risperidone in Long-Acting Injectable Form (Consta)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 126, "start_date": "2006-03", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2023-03-01", "last_synced_at": "2026-10-03T22:19:51.192Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00330551" }, { "nct_id": "NCT04624243", "title": "Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Elpipodect", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Placebo to MK-8189", "type": "DRUG" }, { "name": "Placebo to risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 499, "start_date": "2020-12-15", "completion_date": "2024-06-21", "has_results": true, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-10-03T22:19:51.192Z", "location_count": 35, "location_summary": "Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 27 more", "locations": [ { "city": "Bentonville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04624243" }, { "nct_id": "NCT00203788", "title": "Improving Work Outcome in People With Recent-onset Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Individual Placement and Support", "type": "BEHAVIORAL" }, { "name": "Workplace Fundamentals Module", "type": "BEHAVIORAL" }, { "name": "Brokered Vocational Rehabilitation", "type": "BEHAVIORAL" }, { "name": "Oral risperidone", "type": "DRUG" }, { "name": "Skills training group", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 87, "start_date": "1999-05", "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2013-07-30", "last_synced_at": "2026-10-03T22:19:51.192Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00203788" }, { "nct_id": "NCT02469155", "title": "A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "ITI-007", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intra-Cellular Therapies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 696, "start_date": "2015-06", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-10-03T22:19:51.192Z", "location_count": 11, "location_summary": "Little Rock, Arkansas • Springdale, Arkansas • Culver City, California + 8 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Culver City", "state": "California" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02469155" }, { "nct_id": "NCT00053703", "title": "Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Risperidone", "type": "DRUG" }, { "name": "Olanzapine (enrollment closed in this treatment)", "type": "DRUG" }, { "name": "Molindone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "19 Years", "sex": "ALL", "summary": "8 Years to 19 Years" }, "enrollment_count": 116, "start_date": "2002-02", "completion_date": "2007-05", "has_results": true, "last_update_posted_date": "2014-03-26", "last_synced_at": "2026-10-03T22:19:51.192Z", "location_count": 4, "location_summary": "Medford, Massachusetts • Chapel Hill, North Carolina • Cleveland, Ohio + 1 more", "locations": [ { "city": "Medford", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053703" }, { "nct_id": "NCT03503318", "title": "Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "TV-46000", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "13 Years to 65 Years" }, "enrollment_count": 544, "start_date": "2018-04-27", "completion_date": "2020-12-03", "has_results": true, "last_update_posted_date": "2023-03-10", "last_synced_at": "2026-10-03T22:19:51.192Z", "location_count": 73, "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 58 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Colton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03503318" }, { "nct_id": "NCT01207414", "title": "Switching to Iloperidone From Other Antipsychotics in Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "iloperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 501, "start_date": "2010-08", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2013-03-15", "last_synced_at": "2026-10-03T22:19:51.192Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Cerritos, California • Costa Mesa, California + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cerritos", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01207414" }, { "nct_id": "NCT02411526", "title": "Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "ZX003 (Risperidone-SABER®)", "type": "DRUG" }, { "name": "Risperdal Consta", "type": "DRUG" }, { "name": "Oral Risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zogenix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 60, "start_date": "2015-02", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2022-10-31", "last_synced_at": "2026-10-03T22:19:51.192Z", "location_count": 1, "location_summary": "Long Beach, California", "locations": [ { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02411526" }, { "nct_id": "NCT00221403", "title": "Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "Risperidone oral solution", "type": "DRUG" }, { "name": "Valproate Oral Solution", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "7 Years", "sex": "ALL", "summary": "3 Years to 7 Years" }, "enrollment_count": 46, "start_date": "2004-09", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2020-10-20", "last_synced_at": "2026-10-03T22:19:51.192Z", "location_count": 2, "location_summary": "Cincinnati, Ohio • Milwaukee, Wisconsin", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00221403" } ] }